Lindbrook Capital’s Arcus Biosciences RCUS Stock Holding History

Lindbrook Capital’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$102	Buy	+13	New	+$151	﹤0.01%	2751
2024 Q3	–	Sell	-128	Closed	-$1.95K	–	2894
2024 Q2	$1.95K	Buy	128 +76	+146%	+$1.23K	﹤0.01%	2346
2024 Q1	$982	Hold	52	–	–	﹤0.01%	2425
2023 Q4	$993	Buy	+52	New	+$831	﹤0.01%	2465
2022 Q3	–	Sell	-59	Closed	-$1K	–	2864
2022 Q2	$1K	Buy	59 +9	+18%	+$220	﹤0.01%	2343
2022 Q1	$2K	Hold	50	–	–	﹤0.01%	2061
2021 Q4	$2K	Hold	50	–	–	﹤0.01%	1814
2021 Q3	$2K	Hold	50	–	–	﹤0.01%	1592
2021 Q2	$1K	Hold	50	–	–	﹤0.01%	1807
2021 Q1	$1K	Hold	50	–	–	﹤0.01%	1775
2020 Q4	$1K	Hold	50	–	–	﹤0.01%	1672
2020 Q3	$1K	Hold	50	–	–	﹤0.01%	1625
2020 Q2	$1K	Hold	50	–	–	﹤0.01%	1611
2020 Q1	$1K	Hold	50	–	–	﹤0.01%	1533
2019 Q4	$1K	Hold	50	–	–	﹤0.01%	1428
2019 Q3	$0	Hold	50	–	–	﹤0.01%	1519
2019 Q2	$0	Hold	50	–	–	﹤0.01%	1485
2019 Q1	$0	Hold	50	–	–	﹤0.01%	1485
2018 Q4	$0	Buy	+50	New	+$584	﹤0.01%	1420

Other funds holding RCUS

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Lindbrook Capital's RCUS Position: Q1 2025 in Review

Lindbrook Capital opened a new position in Arcus Biosciences (RCUS) in Q1 2025: 13 shares worth $102. The stake represents ﹤0.01% of the portfolio and ranks #2751 among its holdings. This is a return to the name: Lindbrook Capital previously reported a position in RCUS as recently as Q2 2024.

Lindbrook Capital first reported a position in RCUS in Q4 2018 and has held it in 19 quarters since. The position peaked at $2K in Q1 2022. 186 funds tracked by Wall St. Rank hold RCUS as of Q1 2025.

Lindbrook Capital held 13 shares of Arcus Biosciences worth $102 as of Q1 2025.
Arcus Biosciences was a new Lindbrook Capital position in Q1 2025.
Arcus Biosciences made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2751 holding.
Lindbrook Capital first reported a position in Arcus Biosciences in Q4 2018 and has held it in 19 quarters since.
Lindbrook Capital's Arcus Biosciences position peaked at $2K in Q1 2022.
186 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.